Page 100 - Early Development News Today

JUNEAU, Alaska (AP) — Alaska state education commissioner Michael Johnson is stepping down from the role he has held for six years on June 30. Gov. Mike Dunleavy's office said Johnson announced his decision during a meeting of the state education board on Wednesday.

Waters Corporation has unveiled new instruments, software, and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™

Waters Corporation has unveiled new instruments, software, and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Investegate announcements from https://immatics.com/, Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

Kristi Graber, a former teacher from North Star Elementary School, finished cleaning out her classroom on Tuesday. Graber left behind white boards and pencil sharpeners to take a new job

Dean’s Seminar Series Aviv Regev, PhD Head of Research and Early Development, Genentech Title & Abstract: “Cell atlases as roadmaps to understand and treat disease” Cells are the basic unit of life, and form a key intermediate between genotype and phenotype, that is essential to explain how the gene variants that contribute to disease risk […]

Excelerate posted positive 1Q22 results and highlighted a strong macro backdrop. Read more to see why we plan to slowly accumulate this stock over time.

Second novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's drug discovery platform and selected for AstraZeneca's drug development portfolioA total of three targets

Following a heart attack, the human body is incapable of repairing lost tissue due to the heart’s inability to generate new muscle. However, treatment with heart progenitor cells could result in the formation of functional heart cells at injured sites. This new therapeutic approach is introduced by an international team in